Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.

ABSTRACT:

Background

Genetic alterations in ARID1A were detected at a high frequency in cholangiocarcinoma (CCA). Growing evidence indicates that the loss of ARID1A expression leads to activation of the PI3K/AKT pathway and increasing sensitivity of ARID1A-deficient cells for treatment with the PI3K/AKT inhibitor. Therefore, we investigated the association between genetic alterations of ARID1A and the PI3K/AKT pathway and evaluated the effect of AKT inhibition on ARID1A-deficient CCA cells.

Methods

Alterations of ARID1A, PI3K/AKT pathway-related genes, clinicopathological data and overall survival of 795 CCA patients were retrieved from cBio Cancer Genomics Portal (cBioPortal) databases. The association between genetic alterations and clinical data were analyzed.

SUBMITTER: Tessiri S 

PROVIDER: S-EPMC8761367 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature